TAAR1 AGONISTS AS A POTENTIAL TARGET IN THE THERAPY OF MENTAL DISORDERS WITH THE DEFICIT OF IMPULSIVE AND COMPULSIVE CONTROL

Cover Page

Cite item

Full Text

Abstract

Receptors associated with trace amines, 1st subtype (TAAR1), are the promising targets for the development of new pharmacological approaches to the treatment of various neuropsychiatric disorders. Currently TAAR1 agonists are undergoing clinical trials as new pharmacologically active agents with antipsychotic action. At the same time, the expression of TAAR1 and the physiological significance of these receptors as regulators of the activity of catecholaminergic structures in the Central nervous system suggest that the activation of TAAR1 can have a therapeutic effect in patients suffering from mental diseases such as obsessive-compulsive disorder and attention deficit hyperactivity disorder, which are accompanied by violations of impulsive and compulsive control. This paper is an attempt to critically evaluate the currently existing data set obtained during testing of TAAR1 ligands in in vivo studies over the past 5 years. The analysis suggests that TAAR1 agonists may provide and have a limited anti-compulsive effect when used in the clinic.

About the authors

I. M. Sukhanov

A.V. Valdman Institute of Pharmacology, I.P. Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: ilia.sukhanov@gmail.com

Sukhanov Ilya

197101, Saint Petersburg

Russian Federation

References

  1. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al. Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci. 2001; 98 (16): 8966–71.
  2. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphetamine, 3,4-methylenedioxymetha mphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001; 60 (6): 1181–
  3. Rutigliano G, Accorroni A, Zucchi R. The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol. 2018; 8: 1–
  4. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al. Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity. J Pharmacol Exp Ther. 2008; 324 (3): 948–56.
  5. Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D, et al. TAAR1 Modulates Cortical Glutamate NMDA Receptor Function. Neuropsychopharmacology. 2015; 40 (9): 2217–27.
  6. Xie Z, Westmoreland S V., Bahn ME, Chen G-L, Yang H, Vallender EJ, et al. Rhesus Monkey Trace Amine-Associated Receptor 1 Signaling: Enhancement by Monoamine Transporters and Attenuation by the D2 Autoreceptor in Vitro. J Pharmacol Exp Ther. 2007; 321 (1): 116–27.
  7. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, et al. The Trace Amine 1 receptor knockout mouse: An animal model with relevance to schizophrenia. Genes, Brain Behav. 2007; 6 (7): 628–
  8. Sotnikova TD, Caron MG, Gainetdinov RR. Trace Amine-Associated Receptors as Emerging Therapeutic Targets. Mol Pharmacol. 2009; 76 (2): 229–
  9. Achat-Mendes C, Lynch LJ, Sullivan KA, Vallender EJ, Miller GM. Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amineassociated receptor Pharmacol Biochem Behav. 2012; 101 (2): 201–7.
  10. Di Cara B, Maggio R, Aloisi G, Rivet J-M, Lundius EG, Yoshitake T, et al. Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA). J Neurosci. 2011; 31 (47):16928–40.
  11. Sukhanov I, Caffino L, Efimova E V., Espinoza S, Sotnikova TD, Cervo L, et al. Increased context-dependent conditioning to amphetamine in mice lacking TAARPharmacol Res. 2016; 103: 206–14.
  12. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U. In Vivo Measurement of Dopamine and Its Metabolites by Intracerebral Dialysis: Changes After d‐ Amphetamine. J Neurochem. 1983; 41 (6): 1769–
  13. Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychoticand antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013; 18 (5): 543–56.
  14. Revel FG, Moreau J-L, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci. 2011; 108 (20): 8485–90.
  15. Revel FG, Meyer CA, Bradaia A, Jeanneau K, Calcagno E, Andre CB, et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology. 2012; 37 (12): 2580–
  16. Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. Pharmacol Ther. 2017; 180: 161–80.
  17. Curatolo P, D’Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr. 2010; 36 (1): 79.
  18. Koo M-S, Kim E-J, Roh D, Kim C-H. Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder. Expert Rev Neurother. 2010; 10 (2):275–90.
  19. Seibell P, Hollander E. Management of Obsessive-Compulsive Disorder. F1000Prime Rep. 2014; 6: 1–6.
  20. Platt B, Beyer CE, Schechter LE, Rosenzweig-Lipson S. Schedule-Induced Polydipsia: A Rat Model of ObsessiveCompulsive Disorder. In: Current Protocols in Neuroscience. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 20p. 1–8.
  21. Sukhanov I, Dorotenko A, Dolgorukova A, Hoener MC, Gainetdinov RR, Bespalov AY. Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats. Neuropharmacology. 2019; 144; 184
  22. Ferragud A, Howell AD, Moore CF, Ta TL, Hoener MC, Sabino V, et al. The Trace Amine-Associated Receptor 1 Agonist RO5256390 Blocks Compulsive, Binge-like Eating in Rats. Neuropsychopharmacology. 2017; 42 (7): 1458–
  23. Cinque S, Zoratto F, Poleggi A, Leo D, Cerniglia L, Cimino S, et al. Behavioral phenotyping of dopamine transporter knockout rats: Compulsive traits, motor stereotypies, and anhedonia. Front Psychiatry. 2018; 9: 1–
  24. Sagvolden T, Johansen EB. Rat Models of ADHD. In: Current topics in behavioral neurosciences [Internet]. 20p. 301–15.
  25. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci. 1998; 18 (6): 1979–86.
  26. Revel FG, Moreau JL, Gainetdinov RR, Ferragud A, Velazquez-Sanchez C, Sotnikova TD, et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry. 2012; 72 (11): 934–42.
  27. Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, et al. Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats. J Neurosci. 2018; 38 (8): 1959–72.
  28. Xue Z, Siemian JN, Johnson BN, Zhang Y, Li JX. Methamphetamineinduced impulsivity during chronic methamphetamine treatment in rats: Effects of the TAAR 1 agonist RO52633Neuropharmacology. 2018; 129: 36–46.
  29. Sukhanov I, Dorotenko A, Bortnikov N, Tur M, Dolgorukova A, Dorofeikova M, et al. Evaluation of effects of the TAAR1 partial agonist RO5263397 on executive cognitive functions. Eur Neuropsychopharmacol. 2019; 29: S261–2.
  30. Evenden JL. Varieties of impulsivity. Psychopharmacology (Berl). 1999; 146 (4): 348–61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Sukhanov I.M.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.